Samsung Biologics clinches 6 million contract from Britain's GSK for consignment production

[Courtesy of Samsung Biologics]

SEOUL -- Samsung Biologics, a leading bio company in South Korea, has clinched a 6 million contract from GlaxoSmithKline (GSK), a British multinational pharmaceutical company, for the consignment production of unspecified medicines. The contract period is until December 31, 2030.  

In a regulatory filing on October 20, Samsung Biologics refused to disclose which drugs are commissioned to produce. Under a partnership with GSK in 2020, Samsung Biologics agreed to supply belimumab, which is sold under the trade name Benlysta to treat systemic lupus erythematosus, and supply GSK’s innovative biopharmaceutical therapies, and provide additional capacity for large-scale biopharmaceutical product manufacturing.

GSK has maintained partnerships with other South Korean companies. For the development of a recombinant vaccine, SK Bioscience has used GSK's adjuvant, which is a drug or other substance, or a combination of substances, that is used to increase the efficacy or potency of certain drugs.